## INTREPID Alliance Antiviral Landscape: Overview of 13 Priority Viral Families\*

As of July 12, 2024, for the 13 viral families with greatest risk of pandemic potential, clinical phase & approved antiviral compounds fall into 9 of 13 and preclinical into 10 of 13.

## **Primarily Respiratory Transmission:**

	Disease Indication (n)**	
Viral Family	Preclinical	Clinical
Adenoviridae	HuAdeno A-G (3)	HuAdeno A-G (0)
Coronaviridae	COVID-19 (73) MERS-CoV (5) SARS-CoV-1 (5)	COVID-19 (29)
Orthomyxoviridae	Influenza (12)	Influenza (9)
Paramyxoviridae	Hendra virus (3) Measles (1) Nipah virus (3) Parainfluenza (0)	X
Picornaviridae	X	Polio (2) Rhinovirus (1)

**X** = absence of preclinical or clinical phase antivirals

## **Primarily Contact/Vector-Mediated Transmission:**

	Disease Indication (n)**	
Viral Family	Preclinical	Clinical
Arenaviridae	Lassa fever (1) Argentine hem. fever (0) Lujo hem. fever (0)	Lassa fever (1) Chapare hem. fever (1)
Filoviridae	Ebola (1) Marburg (3)	Ebola (2)
Flaviviridae	Dengue (4) West Nile (1) Yellow fever (3) Zika (2)	Dengue (3) Japanese encephalitis (0)
Hantaviridae	Hantavirus (1)	X
Nairoviridae	X	Crimean Congo hem. fever (2)
Peribunyaviridae	X	X
Poxviridae	Mpox (2) Smallpox/Other poxviruses (1)	Mpox (1)
Togaviridae	Chikungunya (3)	X

<sup>\*</sup>As of July 12, 2024; \*\*Number of compounds in ongoing development; those with (0) only have "Archived" compounds.





## Interested in engaging with us?

We welcome all feedback through our online portal. As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact <a href="mailto:nina@intrepidalliance.org">nina@intrepidalliance.org</a>.

- intrepidalliance.org
- in linkedin.com/company/intrepid-alliance

